Comparative efficacy and safety of distinct PD-1 antibodies in unresectable advanced or recurrent gastric and gastroesophageal junction cancer: a network meta-analysis of randomized controlled trials
OncologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- BMC gastroenterology
- Publicado em
- 28 nov 2025
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Comparative efficacy and safety of distinct PD-1 antibodies in unresectable advanced or recurrent gastric and gastroesophageal junction cancer: a network meta-analysis of randomized controlled trials
Mengting Wang, Jun Li, Shiju Shen, Linshan Chen, Bo Jia
Descritores MeSH
- Neoplasm Recurrence, Local
- Stomach Neoplasms
- Esophageal Neoplasms
- Esophagogastric Junction
- Programmed Cell Death 1 Receptor
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Antibodies, Monoclonal, Humanized
- Nivolumab
- Progression-Free Survival
Veja também
Estudos relacionados
- Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
- Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis
- Anti-PD-1 and anti-PD-L1 antibodies for glioma
- Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials